RNASE2

Across TCGA pan-cancer cohorts, RNASE2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RNASE2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RNASE2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RNASE2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC and CCRCC are the cancer types where RNASE2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.236	0.781	.009	11	view →
CCRCC	DFS	Quartile	All	0.920	0.546	.008	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RNASE2–PDAC (OS)

Open the PDAC breakdown →